AUDC vs EXOD

The company exhibits a weak Piotroski F-Score of 4/9, indicating marginal financial health, and lacks an Altman Z-Score, limiting distress risk assessment. While profitability metrics like gross margin and ROE are relatively solid, growth is sluggish and valuation multiples are mixed. The stock trades above the Graham Number of $7.99 but below the intrinsic value estimate of $9.71, suggesting modest undervaluation. However, weak earnings consistency, declining price trends, and low analyst coverage temper optimism.

EXOD exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total failure across all fundamental health benchmarks. The company is suffering from a severe revenue collapse, with YoY growth at -34.40% and Q/Q growth at -36.16%, coupled with negative operating margins of -32.33%. While the current ratio of 13.49 suggests high short-term liquidity, the massive 81.9% one-year price decline and bearish insider sentiment signal a lack of confidence in the business model's sustainability. The stock is currently trading near its book value (P/B 0.98), but the lack of earnings growth makes this a value trap rather than a bargain.